Skip to main content

Ardelyx, Inc.

ARDX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001437402

In the last 90 days, Ardelyx, Inc. insiders filed 0 open-market purchases and 9 sales; 250 institutions reported holding it in 13F filings for Q2 2026, worth $906.4M in total; no superinvestor holds it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $697.1K in total
9
13F holdersQ2 2026, +10 vs. previous quarter
250
13F valueReported value at the end of Q2 2026
$906.4M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding ARDX, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding ARDX at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Ardelyx, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 25, 2026 (view filing)7:19 PM ETAug 214 daysHohenleitner SusanChief Financial OfficerSSale−1.56K$3.86−$6.01K−0.7%227.5K after
Aug 25, 2026 (view filing)7:17 PM ETAug 214 daysReilly Joseph JamesSee RemarksSSale−3.98K$3.86−$15.4K−2.7%145.9K after2 lots
Aug 25, 2026 (view filing)7:16 PM ETAug 214 daysBishop John ESee RemarksSSale−19.8K$3.86−$76.2K−5.9%317.1K after2 lots
Aug 25, 2026 (view filing)7:15 PM ETAug 214 daysBrady James ParkerChief Human Resources OfficerSSale−15.1K$3.86−$58.4K−5.8%245.9K after2 lots
Aug 25, 2026 (view filing)7:13 PM ETAug 214 daysFoster Eric DuaneChief Commercial OfficerSSale−8.56K$3.86−$33.0K−2.0%409.4K after3 lots
Aug 25, 2026 (view filing)7:11 PM ETAug 214 daysKelliher MikeChief Business OfficerSSale−7.76K$3.86−$29.9K−2.2%349.7K after3 lots
Aug 25, 2026 (view filing)7:09 PM ETAug 214 daysWilliams Laura AChief Patient OfficerSSale−10.7K$3.86−$41.4K−2.8%367.5K after4 lots
Aug 25, 2026 (view filing)7:07 PM ETAug 214 daysRaab MichaelPresident & CEOSSale−58.6K$3.86−$225.9K−3.5%1.62M after4 lots
Jul 17, 2026 (view filing)4:09 PM ETJul 152 daysRaab MichaelPresident & CEOSSale−41.7K$5.06−$210.9K−2.4%1.68M after10b5-1
Jun 22, 2026 (view filing)Jun 184 daysWilliams Laura AChief Patient OfficerSSale−81.9K$5.99−$490.6K−17.8%378.2K after10b5-1

Top 10 13F holders, Q2 2026

The largest institutional positions in Ardelyx, Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 250 holders
Institutions holding ARDX in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
BlackRock, Inc.23,504,630$119.9M0.00%+2,340,498+11.1%Added
Rubric Capital Management LP16,202,700$82.6M0.76%+14,341,804+770.7%Added
Millennium Management LLC13,900,773$70.9M0.05%−3,941,597−22.1%Reduced
State Street Corp13,356,128$68.1M0.00%−248,179−1.8%Reduced
Vanguard Capital Management LLC10,471,494$53.4M0.00%+105,982+1.0%Added
Nomura Asset Management International Inc.9,546,732$48.7M0.07%+1,377,363+16.9%Added
Vanguard Portfolio Management LLC8,026,774$40.9M0.00%+1,365,081+20.5%Added
Geode Capital Management, LLC6,401,736$32.7M0.00%+394,281+6.6%Added
Jupiter Topco LLC5,302,311$27.0M0.01%+5,302,311New
Two Sigma Investments, LP5,209,823$26.6M0.02%+935,780+21.9%Added